echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > ASCO 2021: Summary Overview and Outlook 7 | PD-1 inhibitor Keytruda hits new progress in first-line therapy for gastric cancer!

    ASCO 2021: Summary Overview and Outlook 7 | PD-1 inhibitor Keytruda hits new progress in first-line therapy for gastric cancer!

    • Last Update: 2021-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Keytruda is the brightest pearl in the immunotherapy era.


    Keytruda is the brightest pearl in the immunotherapy era.


    Merck said at the online American Society of Clinical Oncology meeting that the combination of Keytruda with Roche’s Herceptin and chemotherapy can reduce tumors in 74.


    Dr.


    Merck

    Ebbinghaus said that Keynote-811 data in Phase 3 showed "very significant therapeutic effects.


    The KEYNOTE-811 study is an ongoing global multi-center, randomized controlled phase III clinical study, which included patients who were previously untreated unresectable or metastatic HER2+ gastric cancer/gastric junction adenocarcinoma; life expectancy >6 In September, the measurable lesions, organ functions and physical status in RECIST v1.


    href="" target="_blank" rel="noopener">


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.